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Abstract 
 
Protein O-glycosylation plays key roles in many biological processes, but the repertoire of O-
glycans synthesized by cells is difficult to determine. Here we describe a new approach termed 
Cellular O-Glycome Reporter/Amplification (CORA), a sensitive method to amplify and profile 
mucin type O-glycans synthesized by living cells. Cells incubated with peracetylated benzyl-α-N-
acetylgalactosamine (GalNAc-α-Benzyl) convert it to a large variety of modified O-glycan 
derivatives that are secreted from cells, allowing easy purification for analysis by HPLC and 
mass spectrometry (MS). CORA results in ~100-1000-fold increase in sensitivity over 
conventional O-glycan analyses and identifies a more complex repertoire of O-glycans in more 
than a dozen cell types analyzed. Furthermore, CORA coupled with computational modeling 
allows predictions on the diversity of the human O-glycome and offers new opportunities to 
identify novel glycan biomarkers for human diseases. 
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Introduction: 
 
Protein glycosylation is a common post-translational modification in all animals that helps to 
create post-genomic diversity1. Although systems-level approaches to evaluate genomes and 
proteomes have revolutionized our understanding of physiology and disease, similar 
approaches for glycomics are lacking in most biological settings. A primary need in glycomics is 
simple and sensitive technologies to analyze all glycans synthesized by cells (the cellular 
glycome)2. This has been challenging due to the diversity and complexity of glycans, low 
abundance of certain glycan species, poor sensitivity of existing glycomics approaches, and 
lack of efficient and unbiased strategies to release glycans from complex samples. Current 
technologies to evaluate glycans in biological samples require their release from 
glycoconjugates by chemo-enzymatic methods, followed by analyses by mass spectrometry 
(MS) and other technologies2. Relatively large amounts of biological samples are often needed 
for detailed structural analyses, limiting the widespread application of glycomics. One way to at 
least partly overcome these challenges would be to “amplify” the glycome, similar to PCR-
hybridization-based technologies for the genome3. Such amplification technology would allow 
analysis of microscale samples of biological material, facilitating clinical and biological 
discovery.  
 
One of the most common types of protein glycosylation is mucin type O-glycosylation (R-
GalNAcα1-O-Ser/Thr where R represents extended structures). O-glycans are present on >80% 
of proteins that traverse the secretory apparatus and are important in many normal and 
pathologic settings4-7. Nonetheless, little is known about how specific O-glycan structures 
regulate biology, largely due to a lack of effective technologies for O-glycomics. In contrast to N-
glycans, which can be released enzymatically, O-glycans require chemical strategies – primarily 
alkaline β-elimination, which is inefficient, potentially biased, may result in O-glycan degradation 
via the peeling reaction, and requires extensive expertise not available in most laboratories8. 
 
To meet these challenges, here we describe a novel method for profiling and amplifying mucin 
type O-glycans from living cells, termed Cellular O-Glycome Reporter/Amplification (CORA). To 
assess the repertoire of glycosyltransferases and glycosylation reactions in the secretory 
pathway for the O-glycome, we developed a chemical O-glycan precursor, peracetylated 
Benzyl-α-GalNAc (Ac3GalNAc-α-Benzyl), which is taken up by living cells, de-acetylated, 
modified by native glycosyltransferases in the presence of nucleotide sugar-donors in the 
secretory pathway, and then secreted into media (Fig. 1). Benzyl-α-GalNAc structurally mimics 
the precursor GalNAcα1-O-Ser/Thr (Tn antigen) in O-glycoproteins9 and its peracetylation 
promotes transport across the plasma membrane10. Living cells incubated with Ac3GalNAc-α-
Benzyl secrete a diverse set of benzyl-α-O-glycans that represent the cellular O-glycome. Using 
CORA, we identified 76 O-glycans, including those observed by traditional alkaline β-
elimination/MS. Importantly, CORA provided ~100-1000-fold enhanced sensitivity, much cleaner 
MS profiles of O-glycans, and revealed novel O-glycans in a variety of cancer and primary cells 
not seen by classic approaches. This simple, sensitive, and versatile method for amplifying and 
profiling the cellular glycome could be a transformational technology in the biomedical sciences 
and allow dynamic studies of O-glycosylation in living cells. 
 
Results 
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Cells efficiently uptake Ac3GalNAc-α-O-Bn and secrete Bn-O-glycans 
 
Mucin type O-glycan biosynthesis begins with transfer of GalNAc to Ser/Thr residues in 
glycoproteins to generate GalNAcα1-O-Ser/Thr (Tn antigen), which T-synthase extends to the 
dominant Core 1 O-glycan Galβ3GalNAcα1-O-Ser/Thr. Bn-α-GalNAc structurally mimics 
GalNAcα1-O-Ser/Thr and has been used as an acceptor in in vitro assays of enzyme activities 
for generating Core 1 and 3 disaccharides11, 12. However, Core 3 GnT is only observed in 
primary GI tissues and not cell lines11, 12. Prior studies have shown that high concentrations of 
Bn-α-GalNAc (2~20mM) can inhibit extension of Core 1 O-glycans in cultured cells13, apparently 
by acting as a surrogate acceptor for T-synthase and compromising extension of the Core 1 O-
glycan on natural glycoprotein acceptors14. However, we hypothesized that Bn-α-GalNAc at low 
concentrations might not inhibit biosynthesis but could be useful as an O-glycan precursor to 
form free Bn-O-glycans representing the cellular O-glycome. We utilized the more highly 
hydrophobic derivative Ac3GalNAc-Bn (Supplementary Fig. 1a) to enhance cellular uptake10 
and predicted that upon entry into cells Ac3GalNAc-Bn would become activated by cytosolic 
esterases to regenerate Bn-GalNAc. Bn-GalNAc would then be transported into the secretory 
pathway, modified by glycosyltransferases, and secreted into media as biosynthetic Bn-O-
glycans that could be easily purified and analyzed by MS. We termed this technology Cellular 
O-Glycome Reporter/Amplification or CORA and the workflow of the technology is described 
Fig. 1. 
 
To test this, we cultured adherent (HEK293) and suspension (Molt-4) cells in complete media 
containing 50µM Ac3GalNAc-Bn or vehicle (DMSO) for 3 days. Putative Bn-O-glycans from 
media were separated from larger material using a cut-off membrane, purified by C18 
chromatography, permethylated, and analyzed by MALDI-TOF-MS. Here as elsewhere we only 
analyzed the permethylated non-sulfated/non-phosphorylated glycans. We observed clean 
MALDI-TOF profiles with Bn-O-glycan compositions corresponding to Core 1 and 2-based 
structures (Fig. 2) from cells cultured with Ac3GalNAc-Bn but not vehicle, indicating efficient 
uptake and modification of the O-glycan precursor by glycosyltransferases in vivo. 
 
To assess whether peracetylation of Bn-α-GalNAc enhanced uptake and subsequent sensitivity, 
we incubated breast cancer cells (MDA-MB-231) with 0-250µM of Ac3GalNAc-Bn or Bn-GalNAc 
for 3 days. Bn-O-glycans with predicted sialylated Core 1 structure were observed at a 
concentration as low as 25µM Ac3GalNAc-Bn, but such derivatives were only observed at the 
highest concentration of 250µM Bn-GalNAc (Supplementary Fig. 2). Thus, peracetylation 
improved the sensitivity, avoiding higher concentrations that might have side effects, as 
explored below. 
 
To optimize conditions, we cultured MDA-MB-231 cells with 0-250µM of Ac3GalNAc-Bn for 2-4 
days. Bn-O-glycans were seen at all time points and concentrations, down to 5µM of 
Ac3GalNAc-Bn for 2 days (Supplementary Fig. 3) and their profiles were stable over time. 
Remarkably, increasing Ac3GalNAc-Bn concentration shifted abundance from disialylated to 
monosialylated Core 2 (Supplementary Fig. 3d), supporting observations that 
glycosyltransferase:substrate ratios drive glycan microheterogeneity15. This shift also suggests 
that a sialyltransferase and/or CMP-NeuAc required for generating disialyl Core 2 is limiting, 
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thus CORA should be performed at low concentrations of Ac3GalNAc-Bn. For most subsequent 
studies, we incubated cells with 50µM Ac3GalNAc-Bn for 3 days. At these conditions, 
Ac3GalNAc-Bn was not toxic to cells (Supplementary Fig. 4) and did not alter cellular 
properties (Supplementary Fig. 5) or cell surface O- or N-glycosylation (Supplementary Fig. 
6, 7). 
  
Synthesis of Core 1-based Bn-O-glycans in cells requires active T-synthase  
 
The above results show that cells cultured with Ac3GalNAc-Bn produce and secrete free Bn-O-
glycans into media containing the Core 1-based structures requiring T-synthase. To confirm that 
Bn-GalNAc can only be utilized by glycosyltransferases involved in mucin-type O-glycan 
biosynthesis, but not other irrelevant or unknown pathway(s), we tested CORA in T-synthase-
competent versus T-synthase-null cells. Biosynthesis of active T-synthase requires a specific 
molecular chaperone Cosmc and genetic or epigenetic disruption of Cosmc results in inactive T-
synthase and consequent expression of Tn and its sialylated version, sialylTn antigens16-18. 
 
Thus, we performed CORA on cells with mutant Cosmc and their wildtype/rescued counterparts. 
Only cells with functional Cosmc and active T-synthase, but not cells with dysfunctional Cosmc 
and inactive T-synthase, secreted Bn-O-glycans when administered Ac3GalNAc-Bn (Fig. 3a-d). 
Furthermore, cells given the isomer Ac3GlcNAc-Bn (Supplementary Fig. 1b) did not secrete 
Bn-O-glycans (Supplementary Fig. 8), but rather no glycan or the simple trisaccharide 
Neu5Ac-Gal-GlcNAc. These demonstrate that CORA faithfully reports the O-glycome and that 
modification in cells requires active T-synthase. 
 
Accuracy of CORA 
 
We compared O-glycome profiles from CORA to β-elimination, available through the CFG 
(http://www.functionalglycomics.org). WEHI-3 and HL-60 cells were analyzed because they 
have complex O-glycomes with unique structures, such as Cad, and extended poly-N-
acetyllactosamines [3Galβ4GlcNAcβ-]n that are challenging to detect by β-elimination of lysates 
but observed on purified glycoproteins19, 20. 
 
From Figure 4 and Supplementary Figures 9-10, the MALDI-TOF-MS and MS/MS profiles 
show that WEHI-3 and HL-60 cells produced 11 and 40 glycan structures, respectively, 
including sialylated Core 1 and 2-based glycans for both cells and Cad antigen in WEHI-3 (Fig. 
4a, b). CORA detected most of the compositions from β-elimination (12 of 13 for WEHI-3, 4 of 7 
for HL-60) and many additional compositions (16 for WEHI-3, 6 for HL-60) (Fig. 4c–e), which 
were generally the most complex, including poly-N-acetyllactosamines with ~3 repeats and I 
antigen. Importantly, the 4 masses observed by β-elimination but not CORA (Fig. 4c, d) are 
Core 1 and 2-based glycans, lacking terminal sialylation, and therefore are most likely 
biosynthetic intermediates, such as from glycoproteins within an intermediate Golgi 
compartment prior to secretion. 
 
To confirm our results, we repeated the experiments twice and obtained nearly identical O-
glycome profiles (Supplementary Fig. 11) and also performed ESI-MS and obtained similar 
results to MALDI-MS and MS/MS (Supplementary Fig. 12). Together, these demonstrate that 
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CORA reflects the cellular O-glycome, which is relatively stable under optimal culture 
conditions. 
 
Sensitivity of CORA 
 
β-elimination often requires ≥107 cells and produces many unassignable peaks21. To determine 
how many cells are needed to get clean, interpretable profiles with CORA, we profiled four cell 
lines each seeded at 5x105, 105, or 2x104 cells. In Figure 5a-d, we obtained O-glycomes from 
all lines seeded at 5x105 and 105 cells and 3 of 4 lines seeded at 2x104 cells (Fig. 5e). 
Significantly, profiles did not change with different cell numbers. The detection of Bn-O-glycans 
from 2x104 cells cultured for 3 days to a total of ~8x104 cells (assuming ~24 hour doubling times) 
represents a ~100-1000-fold increase in sensitivity compared to β-elimination. 
 
Profiling the O-glycome of mouse and human primary cells 
 
Because primary cells differ metabolically from cancer cells22, we validated CORA on primary 
human and mouse cells. First we profiled immortalized murine pulmonary endothelial cells 
(mPECs) with or without Cosmc from Tie2-Cre+;CosmcF/+  mice23 to determine if, similar to other 
cell lines, Bn-O-glycan secretion requires functional Cosmc. mPECs with functional Cosmc, but 
not deleted Cosmc, secreted Bn-O-glycans (Supplementary Fig. 13a, b). Next we isolated wt 
Tn(-) mPECs from these same mice and performed CORA (Supplementary Fig. 13c, d). 
Glycan structures were similar in immortalized and primary mPECs, except for a glycan with the 
disialyl motif, only found in the primary cells. However, the ratio of O-glycans differed in these 
two mPECs, suggesting that transformation may disrupt glycan biosynthesis, as in human 
tumors24. 
 
Next, we evaluated primary human dermal fibroblasts and umbilical vein endothelial cells 
(HUVECs) (Fig. 6, Supplementary Fig. 14-15). HUVECs produced 43 O-glycans, including 
those containing poly-N-acetyllactosamine, Lewis structures, blood group antigens, and I 
antigen, as confirmed by MS/MS (Fig. 6a, Supplementary Fig. 14a, 15). Fibroblasts also 
produced at least 18 glycans (unique masses), including poly-N-acetyllactosamine, Lewis 
structures, and blood group antigens (Fig. 6b, Supplementary Fig. 14b). O-glycans are 
essential for endothelia but unexplored in fibroblasts; however, their remarkable diversity, 
described here for the first time, highlights their potential importance.  
 
Ac3GalNAc-Bn treatment does not alter cellular properties 
 
High concentrations (2~20 mM) of GalNAc-Bn can disrupt cell morphology and glycosylation14. 
To avoid this, we used a low concentration of 50µM Ac3GalNAc-Bn and assessed toxicity by 
XTT after 3 days culture. XTT conversion to a formazan dye was similar in vehicle and 
Ac3GalNAc-Bn treated cells (Supplementary Fig. 4), indicating that 50µM Ac3GalNAc-Bn was 
not toxic to cells. After culture with Ac3GalNAc-Bn, we also assessed gross morphology by light 
microscope and cellular granularity by side scatter on FACS. No changes were observed 
(Supplementary Fig. 5), demonstrating intact cell viability and morphology. 
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Low concentrations of Ac3GalNAc-Bn do not significantly affect O- and N-glycosylation 
of glycoproteins in cells 
 
To investigate whether low concentrations of Ac3GalNAc-Bn alter protein O- or N-glycosylation 
in cells, we incubated cells with 50µM Ac3GalNAc-Bn for 3 days and blotted with multiple lectins. 
Lectins allow a sensitive ‘global’ analysis of protein glycosylation (specific terminal sugar and 
linkage-specific determinants) in multiple glycoproteins, which is preferred over conventional MS 
analysis of released glycans that again might be limited in sensitivity and does not provide 
linkage information. We used PNA to assess O-glycosylation (Supplementary Fig. 6) and 
RCA-I, SNA, and MAL-I to assess N-glycosylation (Supplementary Fig. 7). No changes in 
lectin binding were observed after culture with 50µM Ac3GalNAc-Bn, demonstrating no apparent 
change in O or N-glycosylation of cellular glycoproteins. 
 
Ac3GalNAc-Bn and Bn-O-glycans are stable in cell culture media 
 
Peracetylation of GalNAc-Bn clearly enhanced production of Bn-O-glycans due to efficient 
cellular uptake of the compound. To evaluate the stability of GalNAc-Bn acetylation, we 
incubated 50µM Ac3GalNAc-Bn in complete media for 3 days. Ac3GalNAc-Bn was recovered 
without significant loss of the signal or appearance of GalNAc-Bn (Supplementary Fig. 16), 
indicating that Ac3GalNAc-Bn is stable in media and not appreciably deacetylated. 
 
Cells might produce cell surface or secreted glycosidases that reshape their glycome1 and 
perhaps modify secreted Bn-O-glycans. However, this is unlikely given that Bn-O-glycan profiles 
are stable across time (Supplementary Fig. 3) and closely resemble those from β-
elimination/MS (Fig. 4). Nonetheless, we directly investigated this scenario using LS174T-Tn(-) 
and Tn(+) cells, with active or inactive T-synthase. We cultured LS174T-Tn(-) cells with 
Ac3GalNAc-Bn and directly analyzed Bn-O-glycans or further incubated this media with LS174T-
Tn(+) cells before analyzing Bn-O-glycans. Because LS174T-Tn(+) cells cannot synthesize O-
glycans beyond Bn-GalNAc, any change in Bn-O-glycan structure would indicate glycosidases. 
Importantly, Bn-O-glycans from LS174T-Tn(-) were not altered after culture with LS174T-Tn(+) 
cells (Supplementary Fig. 17), showing that Bn-O-glycans are stable after secretion from 
cultured cells. 
 
CORA promotes the discovery of novel glycans  
 
MS/MS sequencing is needed for definitive determination of glycan structure. However, this is 
often not possible with β -elimination because of insufficient material. Using CORA, we 
performed MS/MS sequencing on HL-60, WEHI-3, and HUVEC cells and observed many 
diverse glycan structures (11 for HL-60, 40 for WEHI-3, 43 for HUVEC) as well as novel and 
unexpected O-glycans, including extended Core 1 (HL-60), Vim-2 (HL-60, HUVEC), disialic acid 
(WEHI-3), and I antigen (WEHI-3, HUVEC) (Fig. 4, 6, Supplementary Fig. 9, 10, 15). Although 
this is the first report of extended Core 1 on HL-60 cells and of Vim-2 and disialic acid on O-
glycans from myelocytic cells, these epitopes have been observed in related contexts or 
structures, indicating that they are biosynthetically reasonable products25-27. 
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The I antigen replaces i antigen on RBCs after embryogenesis, but had not been identified on 
O-glycans from other cell lineages, except in secretions28. The discovery of I antigen on O-
glycans from 2 distinct non-RBC cell lineages suggests that this may be a common, yet 
unappreciated structure. We have no explanation as to why I antigen was not previously 
observed on O-glycans from these cell lines, except that in general, O-glycans released by β-
elimination are present in insufficient quantities to identify larger O-glycans in the high mass 
range and when larger O-glycans are identified, MS/MS usually is not feasible. As CORA is an 
amplification technology, it permits analyses of small numbers of cells since they continuously 
produce more Bn-O-glycans, thus amplifying their O-glycomes. 
 
CORA provides information to evaluate the complexity of cellular O-glycome 
 
The complete repertoire of O-glycans is not known. Here we analyzed 18 cell lines including 
primary cells and Cosmc-deficient cells and identified 57 unique O-glycan compositions 
(Supplementary Table 1, 2). Detailed MS/MS structural characterization on 3 of these cells 
(HUVEC, HL-60, WEHI-3) revealed 76 unique structures, derived from 48 unique compositions 
(#structures:#compositions = 1.6) (Supplementary Table 3). From our 18 cell lines, we 
evaluated the frequency of cell lines expressing a given glycan composition (Supplementary 
Fig. 18a, b, Supplementary Table 2) and determined that a few outstanding cell lines 
encompassed most of the complexity of all 18 glycomes (Supplementary Fig. 18c). To 
estimate the size of the non-sulfated/phosphorylated cellular O-glycome, we developed a 
computational model to predict the number of unique O-glycan compositions (Y) we would 
observe on average from a given number of cell lines (X). Our data best fit the equation Y = 
10^(0.5856*log(X) + 1.024) (Supplementary Fig. 19), which predicts that the estimated 200 cell 
types in the human body produce 235 unique compositions. Using the observation above that 
the number of glycan structures may be 1.6-fold more than the number of compositions, we 
could thus predict that there are 1.6x235=376 non-sulfated/phosphorylated structurally different 
O-glycans in the human body. This is the first estimate of the size of the human cellular O-




Here we show that CORA provides a sensitive new approach to both amplify and profile the 
mucin-type O-glycome in living cells. O-glycans are present on most secreted and cell surface 
proteins, but previous strategies for O-glycomics have limited their investigation. Compared to 
traditional methods for O-glycan analysis, CORA 1) amplifies the O-glycome, 2) bypasses 
glycan release, 3) avoids O-glycan degradation, 4) enhances sensitivity ~100-1000x, 5) 
increases signal-to-noise, 6) detects novel complex O-glycans, 7) provides a biosynthetic 
process for real-time studies of dynamic changes in the O-glycome of living cells, and 8) is 
technically simple with potential for wide-spread and high-throughput application. 
 
It is interesting that CORA is effective at low concentrations (<250µM) and incubation times with 
no observed impact on cellular properties or glycosylation. Prior studies had shown that 
treatment of cells with high concentrations of Bn-α-GalNAc produced mainly small 
Galβ3GalNAcα1-O-benzyl and sialyl-Galβ3GalNAcα1-O-benzyl derivatives29, 30. However, the 
success of CORA using low concentrations of this new Ac3GalNAc-Bn derivative as a precursor 
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indicates that it is readily taken up by live cells, converted to Bn-α-GalNAc, efficiently utilized by 
the T-synthase, and further accessed by a wide range of enzymes in the secretory pathway, 
including the most terminal types of glycan modifications and extensions.  
 
This approach may allow assessment of the total diversity and repertoire of O-glycans in an 
animal O-glycome. Recent studies using transfected CHO cells engineered to express all major 
O-glycan core structures, along with chemical release techniques, identified ~70 different glycan 
structures31. The repertoire of O-glycans is likely much larger, as mucin-type O-glycan 
determinants have been estimated to be nearly 1,000, with probably <500 non-sulfated O-
glycans32. In this regard, our computational modeling allowed us to predict the size of the non-
sulfated/phosphorylated animal O-glycome to be in the range of ~376 unique glycan structures. 
What drives this diversity? Amplification of an entire O-glycome from a simple chemical 
precursor suggests that the biosynthetic machinery and not diverse protein substrates drives O-
glycan heterogeneity. 
 
O-glycans are altered in cancer7, but limitations in O-glycomics have made it difficult to define 
these changes. The distinguishing features of CORA enable analysis of the O-glycome of 
commonly available tumor cell lines without the need for chemical cleavage techniques. Such 
approaches involving β-elimination and treatment with alkaline borohydride, as originally 
developed by Carlson in 196633, lead to peeling reactions at the reducing end and partial loss of 
glycan integrity8. Theoretically, CORA could also be applied to small numbers of fresh tumor 
cells excised from patients and be used to monitor changes in the O-glycome during tumor 
progression, cellular differentiation, maturation, and in the presence of various stimuli.  
 
An advantage of CORA is that live cells are used to generate the O-glycome, but the cells 
afterward can also be analyzed by conventional techniques if desired for comparative analyses. 
Advances in cell and organoid culture, have enabled culture of many normal and diseased 
tissues34-37, yet glycan release is often not sufficiently sensitive to analyze such precious 
specimens. CORA could address this challenge by amplifying the glycome. Although we have 
limited our analyses to mucin type O-glycans, this may be a general strategy for amplifying and 
profiling many classes of glycosylation, with appropriate precursors. While we used small 
numbers of cells for glycan analysis, large numbers of cells in continuous culture could also be 
used as glycan biosynthesis factories to prepare any and all natural O-glycans, even those 
difficult to synthesize chemically. Bn-O-glycans or their derivatives could be isolated to generate 
therapeutic glycans, test the roles of unusual glycans in cell recognition or growth, or for display 
in glycan microarrays. Amplifying the O-glycome by CORA offers a new paradigm in cellular 
glycomics that will enable new types of investigations in a wide range of basic and clinical 






Benzyl-α-D-GalNAc was purchased from Sigma. Benzyl-α-D-GlcNAcAc3 and 4MU-α-D-GalNAc 
were purchased from Carbosynth. Benzyl-α-D-GlcNAcAc3 was generated by addition of 2:1 
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pyridine:acetic anhydride to Benzyl-α-D-GalNAc for 1 hr at 65°C in molar excess, dried by 




Molt-4, Jurkat (clone E6-1), LS174T, HL-60, WEHI-3, HUVEC, and human dermal fibroblasts 
were purchased from ATCC. Lox were a kind gift from Dr. Oystein Fodstad. MKN45, Colo205, 
MDA-MB-231, and MCF7 were a kind gift from Dr. Henrik Clausen. Tn(-) and Tn(+) LS174T 
were subcloned from a mixed population as previously described17. Lox and Jurkat were 
transfected with full length Cosmc or empty vector (pcDNA3.1+) and selected by G418. Tn(-) 
cells were further sorted by FACS. Molt-4, Jurkat, Lox, HL-60, MKN45, and Colo205 were 
cultured in RPMI (Corning) supplemented with 10% FBS and 2% P/S. LS174T, MDA-MB-231, 
and MCF7 were cultured in DMEM (Corning) supplemented with 10% FBS and 2% P/S. MCF7 
were further supplemented with 0.01mg/ml insulin. WEHI-3 were cultured in Iscove’s (Corning) 
supplemented with 10% FBS, 0.05mM 2ME, and 2% P/S. HUVEC and human dermal 
fibroblasts were cultured with endothelial cell growth kit-VEGF (ATCC) and fibroblast growth kit- 
low serum (ATCC) as instructed. All cells were cultured on plastic, except HUVECs, which were 
cultured on plastic pre-coated with 0.1% gelatin.  
 
Administration of compound 
 
Ac3GalNAc-Bn or Bn-GalNAc was dissolved to 50 or 100mM in DMSO and further diluted to 5 – 
250µM in complete media with 5% FBS, except for HUVECs and human dermal fibroblasts 
which were incubated in ATCC pre-formulated media. Media with compound was administered 
1 day (most cells) or 2 days (HUVEC, human dermal fibroblasts) after seeding. Cells were then 
incubated 2 – 4 days with compound before collecting media. 
 
Glycan purification from media 
 
Compound was added to complete media and collected after incubation with cells. Media was 
run over 10kDa centrifugal filter (Amicon – Ultra 4, Millipore) for ~30 minutes at 2465xg and flow 
through was collected. Bn-O-glycans were subsequently purified from flow through by Sep-Pak 
3cc C18 cartridge (Waters) by gravity chromatography. The column was equilibrated with 2 x 
2ml acetonitrile, then 4 x 2 ml 0.1% TFA. Media was applied and then column washed with 4 x 
2ml 0.1% TFA. Bn-O-glycans were then eluted with 2 x 1.5 ml 50% acetonitrile/0.1% TFA. 
Eluent was divided into 3 fractions, centrivapped to remove organic solvents, and lyophilized. 
 
Permethylation and glycan analysis 
 
Dried samples were permethylated by standard procedures38. Two-hundred µl NaOH/DMSO 
slurry was added to samples followed by 200µl methyl iodide. Samples were shaken for 30 
minutes and then spun down at 5000xg for 5 minutes. Supernatant was collected and 
chloroform extraction performed to isolate permethylated glycans. Five hundred µl chloroform 
and 500µl water were added to supernatant, mixed, and centrifuged 5000xg for 1 minute. Two 
more washes with 500µl water were performed before evaporating chloroform by centrivap for 
30 minutes. Bn-O-glycans were then resuspended in 25 or 50 µl 50% methanol. 0.5µl matrix 
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(10mg/ml 2,5-dihydrobenzoic acid (Sigma), 50% acetonitrile, 0.1% TFA) and 0.5µl sample were 
spotted on an Anchorchip target plate, air dried, and analyzed by MALDI-TOF mass 
spectrometry using Ultraflex-II TOF-TOF system (Bruker Daltonics). Peak masses were 
identified and structures assigned by composition and knowledge of glycan biosynthetic 
pathways, or MS/MS where indicated. This procedure only detects non-sulfated/phosphorylated 
structures; however, these modifications have not been previously reported from cells in our 
study. 
 
Cell and enzyme assays 
 
T-synthase and mannosidase assay were performed as previously described9. Briefly, 4MU-
GalNAc was incubated with cell lysate and reaction mix containing O-glycanase and UDP-Gal in 
triplicate for 45 minutes at 37°C to assay T-synthase. O-glycanase releases 4MU from 4MU-
Core 1, which can be assessed in a fluorimeter. Reaction mix without UDP-Gal is used as 
control. To assess mannosidase activity, 4MU-mannoside was added to lysate in reaction mix in 
triplicate for 45 minutes at 37°C. Boiled lysate was used as control. Mannosidase releases 4MU 
from 4MU-mannoside. Fluorescence was converted to specific activities for T-synthase and 






XTT was performed per manufacturer instructions (ATCC) to assess cell viability after 




Primary ECs were obtained from EHC-Cosmc mice23 and isolated from lung as previously 
described, with minor modifications39, 40. Briefly, murine lung was dissected, finely minced, and 
digested with 2 mg/ml type I collagenase (Worthington) at 37°C for 1 hr. Cell suspensions were 
filtered through a 70 µm strainer and then cultured in complete DMEM with endothelial cell 
growth supplement (Sigma). ECs were purified from culture with anti-PECAM-1 (CD31), and 
anti-CD102 (clone 3C4; BD) using Dynabeads®. Tn(+)-ECs were isolated with biotin-labeled 
anti-Tn antibody and Dynabeads® Biotin Binder (Invitrogen). Immortalized ECs were generated 
from primary ECs transfected with pPSVE1-B1a (from Jeffrey D. Esko, UCSD, La Jolla, 




ECs were grown on 0.1% gelatin-coated chamber slides, fixed with 4% paraformaldehyde for 1 
hr, and stained with anti-CD31 and anti-Tn antibodies. Staining was performed per the 
manufacturer’s protocol (Zymed Laboratories) and visualized by Ix71 Olympus microscope with 
Deltavision Software Suite 6.0 (GE Healthcare). 
 
Lectin blots 
	   12	  
 
Biotin-labeled Sambucus nigra (SNA), Ricinus communis agglutinin I (RCA-I), and Maackia 
amurensis I (MAL-I) lectins were purchased from Vector and HRP-labeled Peanut agglutinin 
(PNA) lectin was purchased from Sigma. Cells were treated with 50µM Ac3GalNAc-Bn or DMSO 
for 3 days and then harvested and lysed by vortexing cell pellet in lysis buffer (0.5% TritonX-100 
in TBS supplemented with protease inhibitor tablet (Roche)) once per 5 minutes for 20 minutes 
over ice. Supernatant was collected after 16000xg centrifugation for 15 minutes at 4°C. Protein 
concentration was determined by BCA (Thermo Scientific) following manufacturer’s instructions. 
Lysates were divided into 2 fractions, and 1 fraction was treated with 1µl neuraminidase 
(Roche)/100 µg lysate at 37°C overnight. Fetuin (Sigma) was used as control for lectin staining 
and enzymatic treatment. Lysates were then boiled in reducing SDS buffer, run on 4-20% Mini-
PROTEAN-TGX gels (BIO-RAD) in Tris/Glycine/SDS running buffer, and transferred by Trans-
Blot Turbo (BIO-RAD) semi-dry system to nitrocellulose. Membranes were rinsed and blocked 
with BSA and Tween-20 in essential buffer (25 mM Tris-HCl, 1 mM CaCl2, 1 mM MgCl2, 0.15 M 
NaCl, pH 7.0) (SNA, RCA-I, MAL-I) or TBS (PNA) for 1 hr. Blocking buffer included 0.5% 
BSA/0.5% Tween-20 for SNA and RCA-I, 0.2% BSA/0.2% Tween-20 for MAL-I, and 5% 
BSA/.05% Tween-20 for PNA. PNA-HRP was incubated at 1:1000 for 1 hr at RT in blocking and 
biotin labeled SNA, RCA-I, and MAL-I were incubated in essential buffer at 1, 0.2, and 1 µg/ml, 
respectively for 1 hr at RT or overnight at 4°C. Blots were washed 15 minutes 3 times with 
TTBS (PNA) or wash buffer (essential buffer, 0.1% Tween-20, for SNA, RCA-I, MAL-I). ECL 
was immediately added to PNA-HRP and films were exposed. Biotin labeled lectins were then 
incubated for 1 hr with 1:5000 streptavidin-HRP at RT in blocking buffer, then washed 15 
minutes, 3 times with wash buffer, 15 minutes once with essential buffer, and then incubated 
with ECL and exposed. Blots were stripped with 25mM glycine, 1% SDS, pH 2 at RT for 30 
minutes and then rinsed with PBS for 10 minutes, 2 times before β-actin staining. Blot was 
reblocked with 5% milk/TTBS (0.05%) for 1 hr RT, washed 5 minutes with TTBS, and incubated 
with 1:3000 anti-β-actin (Santa Cruz) in block overnight. Blot was washed 5 minutes, 4 times 
with TTBS, and incubated with 1:3000 HRP labeled secondary at RT for 45 minutes. Blot was 
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Figure 1. Overview of Cellular O-glycome Reporter/Amplification (CORA). Cells are incubated 
with chemical O-glycan precursor or primer (Benzyl-α-D-GalNAc), which is peracetylated 
(Ac3GalNAc-Bn) to facilitate passive transport across the plasma membrane. Cytosolic 
esterases generate Bn-GalNAc, which is taken up in the Golgi and modified by native 
glycosyltransferases during anterograde transport. Elaborated Bn-O-glycans are secreted into 
the media, purified, and analyzed by MS (reported here), HPLC, or printed on glycan microarray 
for interrogation by GBPs. 
 
Figure 2. Bn-O-glycans produced by HEK293 and Molt-4 cells. 50µM Ac3GalNAc-Bn or DMSO 
was administered to (a) HEK293 or (b) Molt-4 cells and incubated for 3 days. Bn-O-glycans 
were purified from media, and one-third of eluent was permethylated and analyzed by MALDI-
MS (composition). Spectra for Ac3GalNAc-Bn and DMSO are off-set, but scaled to same 
absolute intensity for each cell. Representative profiles are shown (n = 2). 
 
Figure 3. The chaperone Cosmc and active T-synthase are required for production of Core 1- 
and 2-based Bn-O-glycans. (a) Loss of Cosmc results in loss of T-synthase activity in LS174T 
colorectal cells, LOX melanoma cells, and Jurkat T cell leukemia. Cells with and without Cosmc 
were subcloned from a mixed population (LS174T) or cells with defective Cosmc were rescued 
with Cosmc or empty vector (LOX, Jurkat). Mannosidase was assayed as control. T-synthase 
and Mannosidase activities were determined in triplicate (n = 2), and a representative 
experiment is shown, mean ± SD of triplicates. (b – d) Only cells with functional Cosmc secrete 
Bn-O-glycans when administered Ac3GalNAc-Bn. Only major glycans are annotated 
(composition) for LS174T (b) for clarity; highly fucosylated minor species as shown in 
Supplementary Fig. 17b were also observed. Spectra for each graph are off-set, but scaled to 
same absolute intensity for each cell. Representative profiles are shown (n = 2). 
 
Figure 4. Accuracy of CORA for profiling the O-glycome. 50µM Ac3GalNAc-Bn was incubated 
with (a) HL-60 and (b) WEHI-3 cells for 3 days and Bn-O-glycans were purified, permethylated, 
and analyzed by MALDI-TOF-MS. Note: Here as in all studies we only analyzed the non-
sulfated/non-phosphorylated glycans. Bn-O-glycans observed by CORA versus alkaline β-
elimination (CFG) of (c) HL-60 and (d) WEHI-3 cells were compared. Compositions are 
depicted for β-elimination and structures are depicted for CORA. Blue boxes indicate glycan 
compositions observed in both CORA and β-elimination. O-glycan MS profiles by β-elimination 
were previously deposited at the Consortium for Functional Glycomics (CFG, 
http://www.functionalglycomics.org). CORA amplified the O-glycome and therefore generated 
sufficient quantities of Bn-O-glycans for high quality MALDI-TOF/TOF-MS/MS analysis. In 
contrast, only MALDI-TOF-MS and compositional analysis was previously performed for CFG 
data, presumably due to insufficient material for MS/MS. (e) The number of glycans (by 
composition) observed in CORA, β-elimination (CFG), or both are indicated for each cell line. All 
spectra of O-glycans were derived from the 75% acetonitrile fraction (see Methods). All 
molecular ions are [M+Na]+. Putative structures are based on composition, tandem MS, and 
biosynthetic knowledge.  
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Figure 5. Sensitivity of CORA. (a) MKN45, (b) Colo205, (c) MDA-MB-231, and (d) MCF-7 cells 
were seeded at 5x105, 105, and 2x104 cells/well in 6 well, 12 well, and 48 well flasks. 50µM 
Ac3GalNAc-Bn was added and Bn-O-glycans were purified and permethylated after 3 days. 
1/150th (6 well, 12 well) or 1/50th (48 well) of total glycans were analyzed by MALDI-MS 
(composition). (e) O-glycomes were observed from all cells seeded at 5x105 and 105 cells/well 
and 3 of 4 cells seeded at 2x104 cells/well. Spectra are off-set for each seeding density and 
scaled relative to maximum intensity. Representative profiles are shown (n = 2). 
 
Figure 6. MALDI-TOF-MS and MS/MS profiling of the O-glycome of primary cells. CORA was 
used to profile the O-glycome of (a) HUVECs and (b) primary human dermal fibroblasts. 
12.5x104 (a, b), 5x104 (b), and 2.5x104 (b) cells were seeded in T25, 6 well, or 12 well flasks, 
respectively. 50µM Ac3GalNAc-Bn was added after 2 days, and Bn-O-glycans were purified, 
permethylated, and analyzed by MALDI after 3 more days. MALDI-TOF/TOF-MS/MS (structure) 
analysis was performed for HUVECs and MS (composition) was performed for fibroblasts. 
Spectra are off-set for each seeding density and scaled relative to maximum intensity. 
 
Supplementary Fig. 1. MALDI profiles of compounds used in this study. (a) Bn-GalNAc, 
Ac3GalNAc-Bn, and (b) Ac3GlcNAc-Bn. 
 
Supplementary Fig. 2. Bn-GalNAc peracetylation increases CORA sensitivity. 0 – 250µM of (a) 
Ac3GalNAc-Bn or (b) Bn-GalNAc was incubated with MDA-MB-231 cells for 3 days before 
collecting, purifying, permethylating, and analyzing Bn-O-glycans by MALDI. Bn-O-glycans were 
observed at a lower initial concentration for peracetylated than unmodified Bn-GalNAc. Spectra 
are off-set for each concentration and scaled relative to maximum intensity. Representative 
profiles are shown (n = 2). 
 
Supplementary Fig. 3. Optimizing concentration of Ac3GalNAc-Bn and incubation time. MDA-
MB-231 breast cancer cells were incubated with 0 – 250µM Ac3GalNAc-Bn for (a) 2, (b) 3, or (c) 
4 days. Profiles did not change across time. (d) Increasing concentration resulted in a shift in 
relative intensities of disialylated Core 2 (glycan #6) to monosialylated Core 2 (glycan #4). (a – 
d) Glycans are labeled 1 – 6 and indicated in (e). Spectra are off-set for each concentration and 
scaled relative to maximum intensity. Representative profiles and graphs are shown (n = 2). 
 
Supplementary Fig. 4. CORA does not alter cell viability. (a) LS174T-Tn(-) and (b) MDA-MB-
231 cells were seeded in 96 well plates in triplicate. 50µM Ac3GalNAc-Bn or DMSO vehicle was 
added to cells for 3 days and XTT assay was performed. One-third and 1/9th dilutions of cells 
were plated as a positive control for reduced cell numbers. No difference was observed 
between Ac3GalNAc-Bn and DMSO for either cell line. Representative experiments are shown 
(n = 2), mean ± SD of triplicates.  
 
Supplementary Fig. 5. CORA does not alter cell morphology or granularity. HEK293 cells were 
incubated for 3 days with (a, e) no treatment, (b, f) vehicle, (c, g) 50µM Ac3GalNAc-Bn, or (d, 
h) 10% DMSO as a positive control. (a – d) Bright field microscopy was used to assess changes 
in cell morphology and (e – h) side scatter was determined by FACS to assess cell granularity. 
No changes were observed upon treatment with 50µM Ac3GalNAc-Bn (n = 2). 
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Supplementary Fig. 6. CORA does not alter cell surface O-glycosylation. (a) Colo205, (b) 
MDA-MB-231, (c) MCF7, and (d) MKN45 cells were incubated with 50µM Ac3GalNAc-Bn or 
DMSO for 3 days. Cells were then collected, lysed, and one fraction was treated with 
neuraminidase before blotting with PNA, which recognizes Core 1 O-glycan. (a – d) Actin was 
used as loading control and (e) fetuin was used as a control for neuraminidase treatment and 
lectin staining. Without neuraminidase treatment, Ac3GalNAc-Bn did not reveal significant PNA 
binding, indicating that 50µM Ac3GalNAc-Bn did not inhibit addition of sialic acid to Core 1 
structure. With neuraminidase treatment, Ac3GalNAc-Bn did not reduce PNA binding, indicating 
that 50µM Ac3GalNAc-Bn did not block Core 1 O-glycan synthesis. Representative blots are 
shown (n = 2). 
 
Supplementary Fig. 7. CORA does not alter cell surface N-glycosylation. (a, f, k, p) Colo205, 
(b, g, l, q) MDA-MB-231, (c, h, m, r) MCF7, and (d, i, n, s) MKN45 cells were incubated with 
50µM Ac3GalNAc-Bn or DMSO for 3 days. Cells were then collected, lysed, and one fraction 
was treated with neuraminidase, before running a denaturing, reducing gel. Lysates were then 
blotted for (a – e) RCA-I, which recognizes Galβ4GlcNAc of N-glycans, (f – j) SNA, which 
recognizes α6-linked sialic acids, (k – o) MAL-I, which recognizes α3-linked sialic acids, and (p 
– s) actin as loading control. (e, j, o) Fetuin was used as a control for neuraminidase treatment 
and lectin staining. Staining with RCA-I, SNA, and MAL-I with or without neuraminidase 
treatment did not differ between Ac3GalNAc-Bn or DMSO incubated cells, indicating that 50µM 
Ac3GalNAc-Bn did not disrupt addition of sialic acid to N-glycan termini or biosynthesis of N-
glycans. Representative blots are shown (n = 2). 
 
Supplementary Fig. 8. Evaluation of potential Bn-glycans produced from cells incubated with 
Ac3GlcNAc-Bn. 50µM Ac3GlcNAcBn or vehicle was incubated with (a) HUVEC, (b) primary 
human dermal fibroblasts, (c) MKN45, and (d) LS174T-Tn(-) and Tn(+) cells. Potential Bn-
glycans were purified, permethylated, and analyzed by MALDI. 
 
Supplementary Fig. 9. MALDI-TOF/TOF-MS/MS analysis of permethylated O-glycans derived 
from HL-60 cells (from Figure 4a): (a) m/z 2202, (b) m/z 2389, (c) m/z 2563. All molecular ions 
are [M+Na]+. Horizontal blue arrows indicate the losses indicated from the molecular ion. 
Vertical blue lines indicate the corresponding peak ion. Letters “m” and “M” in bold characters 
suggest minor and major abundances respectively.  
 
Supplementary Fig. 10. MALDI-TOF/TOF-MS/MS analysis of permethylated O-glycans derived 
from WEHI-3 cells (from Figure 4b): (a) m/z 1853, (b) m/z 2460, (c) m/z 2507, (d) m/z 2956, (e) 
m/z 3113, (f) m/z 3358. All molecular ions are [M+Na]+. Horizontal blue arrows indicate the 
losses indicated from the molecular ion. Vertical blue lines indicate the corresponding peak ion. 
Letters “m” and “M” in bold characters suggest minor and major abundances respectively.  
 
Supplementary Fig. 11. Reproducibility of CORA. (a, b) Ac3GalNAc-Bn was added to HL-60 
cells and Bn-O-glycans were purified, permethylated and analyzed. MALDI-MS profiles from two 
independent experiments are shown and nearly identical. MALDI-MS/MS experiments 
described in Fig 4a. were independently performed but used same material as those used for 
(a) here. Ac3GalNAc-Bn and DMSO are off-set, but scaled to same absolute intensity for each 
experiment. 
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Supplementary Fig 12. Analysis of HUVEC, MKN45, and WEHI-3 O-glycans by ESI-MS. 50µM 
Ac3GalNAcBn was incubated with (a) HUVEC, (b) MKN45, and (c) WEHI-3 cells for 3 days and 
Bn-O-glycans were purified, permethylated, and analyzed by LTQ Orbitrap Hybrid MS. Glycans 
indicated were not detected in vehicle only control (not shown). 
 
Supplementary Fig. 13. O-glycome of murine pulmonary endothelial cells. Tn(-) and Tn(+) 
murine pulmonary endothelial cells (mPECs), with or without Cosmc, respectively, were 
obtained from mosaic EHC-Cosmc+/- mice (immortalized) or EHC-Cosmc+/y or -/y mice (primary). 
Tn expression and CD31 (an endothelial marker) was analyzed by immunofluorescence for (a) 
immortalized and (b) primary cells. Ac3GalNAc or DMSO was added to (a, b) immortalized or (c, 
d) primary cells and Bn-O-glycans were purified after 3 days, permethylated, and analyzed by 
MALDI. Similar O-glycan structures were observed in immortalized and primary cells; however, 
relative ratios of O-glycans differed. Spectra are off-set, but scaled to same absolute intensity 
for each cell type (primary, immortalized). Representative profiles are shown (n = 2). 
 
Supplementary Fig. 14. Profiling the O-glycome of Primary Cells. Ac3GalNAc-Bn or DMSO was 
added to (a) HUVECs or (b) primary human dermal fibroblasts seeded at 12.5x104, 5x104, or 
2.5x104 cells/well. Glycan structures and masses are omitted for clarity, but similar to those 
indicated in Figure 6. Spectra are off-set, but scaled relative to absolute intensity for cells 
seeded at a given density and relative to maximum intensity across cell densities for a given cell 
type. Representative profiles are shown (n = 2). 
 
Supplementary Fig. 15. MALDI-TOF/TOF-MS/MS analysis of permethylated O-glycans derived 
from HUVEC cells (from Figure 6): (a) m/z 1578, (b) m/z 2027, (c) m/z 2303, (d) m/z 2389, (e) 
m/z 2651, (f) m/z 2838. All molecular ions are [M+Na]+. Horizontal blue arrows indicate the 
losses indicated from the molecular ion. Vertical blue lines indicate the corresponding peak ion. 
Letters “m” and “M” in bold characters suggest minor and major abundances respectively.  
 
Supplementary Fig 16. Stability of acetylation in complete media. (a) 50µM Bn-GalNAc, 
Ac3GalNAc-Bn, or vehicle was added to DMEM with 5% FBS and incubated at 37°C, 5% CO2 
for 3 days. Media was directly analyzed by MALDI (n = 2). 
 
Supplementary Fig. 17. Stability of O-glycans in media with cells. (a) LS174T-Tn(-) cells were 
seeded overnight. Ac3GalNAc-Bn was added. After 3 days media was collected and stored for 
further analysis or mixed 1:1 with fresh media and incubated for 3 days with LS174T-Tn(+). (b) 
Bn-O-glycans were then analyzed to assess cell or media-associated glycosidase or non-
enzymatic degradation. Profiles were nearly identical for 3 and 6 day incubations, indicating that 
Bn-O-glycans are stable and not degraded by cells or media. Spectra are off-set and scaled 
relative to maximum intensity. Representative profiles are shown (n = 2). 
 
Supplementary Fig. 18. Glycan frequency across cell lines evaluated in CORA. Histograms 
were generated based on data from Supplementary Table 2 indicating (a, b) number of cells 
lines expressing a given glycan (mass listed on x-axis). (b) Glycans were reordered from 
glycans expressed in greatest number of cells to glycans expressed in least number of cells. 
Eight unique glycans were each observed in >5 cell lines, 17 glycans in 2 – 5 cell lines, and 32 
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glycans in at most 1 cell line. (c) Cells were arranged in descending order from cells expressing 
most glycans to cells expressing fewest glycans. Then number of new glycans observed with 
evaluation of each additional cell line was determined. We have only considered non-sulfated 
and non-phosphorylated O-glycans in this study, in part because these modifications have not 
been previously reported in our 18 cell lines. 
 
Supplementary Fig. 19. Computational model to estimate size of non-sulfated human cellular 
O-glycome. Data from CORA was input into a custom computational model generated in 
MATLAB that determines # of unique glycan masses (Y) observed given X number of randomly 
selected cells. (a) 256 iterations were plotted for each X (1 to 18) and Y was reported +/-SD. 
Nonlinear regression was performed to generate a best-fit line using Prism. Visually satisfactory 
models (Semi-log, log-log, quadratic) were compared by F test or AIC to determine best-fit. 95% 
prediction band was also plotted. SE of slope and Yintercept as well as R2 are reported. This 
equation has no upper-limit suggesting that evaluation of more cells would on average identify 
more glycans. As described we use this equation to predict the size of the non-
sulfated/phosphorylated human cellular O-glycome to be 376. This represents a lower limit as 
there are probably >200 cell types in the human body, a given cell type may express different 
glycans in different environments, and we have only considered the non-sulfated and non-
phosphorylated O-glycans. 
 
Supplementary Table 1. Cell lines and primary cells. 
 
Supplementary Table 2. Glycan masses and compositions. 
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